Pulmonary fibrosis inhibited by pentraxin-2/SAP in research study

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today the publication of collaborative research in the International Journal of Biochemistry ...

Bacterial colonization of the lung also depends on the host genome

The lung is by no means a sterile place, as was assumed for a long time. In fact, it actually harbors a diverse microbial ecosystem. We know from previous studies that changes in the lung microbiome are associated with diseases ...

Team develops nanobody technology against liver inflammation

Mathieu Vinken, a professor in the In Vitro Toxicology and Dermato-cosmetology (IVTD) lab at the Vrije Universiteit Brussel, and doctoral student Raf Van Campenhout have developed a technique based on nanobody technology ...

Urban biodiversity to lower chronic disease

Replanting urban environments with native flora could be a cost effective way to improve public health because it will help 'rewild' the environmental and human microbiota, University of Adelaide researchers say.

page 11 from 18